v3.25.2
Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended
Jul. 27, 2025
Apr. 27, 2025
Jul. 28, 2024
Jul. 27, 2025
Jul. 28, 2024
Jan. 26, 2025
Cash flows from operating activities:            
Net loss $ (27,064)   $ (170,295) $ (7,719) $ (193,454)  
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:            
Depreciation and amortization       20,504 23,071  
Amortization of right-of-use assets       2,702 3,189  
Investment impairments and credit loss reserves, net 0   0 0 1,109  
Goodwill impairment 41,991   0 41,991 0  
Accretion of deferred financing costs       2,525 4,758  
Write-off of deferred financing costs 364   5,497 516 5,497  
Loss on extinguishment of debt       0 143,467  
Interest rate swap termination       (729) 0  
Deferred income taxes       4,848 (934)  
Share-based compensation       24,132 32,372  
Loss on disposition of business operations and assets       42 91  
Equity method income 62   0 (984) (50)  
Gain from sale of investments       0 (277)  
Corporate-owned life insurance, net       1,389 1,670  
Changes in assets and liabilities:            
Accounts receivable, net       9,218 (18,701)  
Inventories       (19,628) (11,031)  
Other assets       (2,770) 3,705  
Accounts payable       11,225 31,084  
Accrued liabilities       (11,440) (26,660)  
Other liabilities       (3,603) (3,990)  
Net cash provided by (used in) operating activities       72,219 (5,084)  
Cash flows from investing activities:            
Proceeds from sales of property, plant and equipment       3 73  
Purchase of property, plant and equipment       (4,534) (4,745)  
Proceeds from sale of investments       536 2,650  
Purchase of investments       0 (434)  
Purchase of intangibles       (2,779) (5,018)  
Proceeds from corporate-owned life insurance       0 4,802  
Premiums paid for corporate-owned life insurance       (3,428) 0  
Net cash used in investing activities       (10,202) (2,672)  
Cash flows from financing activities:            
Payments of term loans (25,000) $ (10,000)   (35,000) 0 $ (441,400)
Proceeds from interest rate swap termination       237 0  
Deferred financing costs       (564) (824)  
Payments for employee share-based compensation payroll taxes       (12,191) (4,185)  
Proceeds from exercise of stock options       500 643  
Distributions to noncontrolling interest       0 (184)  
Net cash used in financing activities       (47,018) (4,550)  
Effect of foreign exchange rate changes on cash and cash equivalents       1,818 (351)  
Net increase (decrease) in cash and cash equivalents       16,817 (12,657)  
Cash and cash equivalents at beginning of period   $ 151,743   151,743 128,585 128,585
Cash and cash equivalents at end of period $ 168,560   $ 115,928 168,560 115,928 $ 151,743
Supplemental disclosure of cash flow information:            
Interest paid       10,035 42,352  
Income taxes paid       3,996 3,809  
Non-cash investing and financing activities:            
Accounts payable related to capital expenditures       507 269  
Accrued deferred financing costs       0 383  
Accrued purchases of intangibles       3,652 0  
Debt extinguished in exchange for common stock       $ 0 $ 188,050